FENC
Fennec Pharmaceuticals Inc.- Healthcare
- Biotechnology
- $381M market cap
Forecast run · Sep 14, 2026Upside rank 781 of 3,136
Model Signal
ForecastQ Daily Probabilities
49.3%
33.3%
23.8%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$10.96
Price target$16.00
Implied move+46.0%
Analysts8
ForecastQ Portfolios
FENC is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.